Genpact (G) Competitors $44.86 +0.78 (+1.76%) Closing price 07/16/2025 03:59 PM EasternExtended Trading$45.25 +0.38 (+0.86%) As of 07/16/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock G vs. CCRN, BR, GPN, JKHY, EXLS, WEX, EEFT, MMS, PAY, and WUShould you be buying Genpact stock or one of its competitors? The main competitors of Genpact include Cross Country Healthcare (CCRN), Broadridge Financial Solutions (BR), Global Payments (GPN), Jack Henry & Associates (JKHY), ExlService (EXLS), WEX (WEX), Euronet Worldwide (EEFT), Maximus (MMS), Paymentus (PAY), and Western Union (WU). Genpact vs. Its Competitors Cross Country Healthcare Broadridge Financial Solutions Global Payments Jack Henry & Associates ExlService WEX Euronet Worldwide Maximus Paymentus Western Union Cross Country Healthcare (NASDAQ:CCRN) and Genpact (NYSE:G) are related companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment. Do institutionals and insiders have more ownership in CCRN or G? 96.0% of Cross Country Healthcare shares are held by institutional investors. Comparatively, 96.0% of Genpact shares are held by institutional investors. 4.9% of Cross Country Healthcare shares are held by company insiders. Comparatively, 3.1% of Genpact shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, CCRN or G? Cross Country Healthcare has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Genpact has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Does the media prefer CCRN or G? In the previous week, Genpact had 10 more articles in the media than Cross Country Healthcare. MarketBeat recorded 11 mentions for Genpact and 1 mentions for Cross Country Healthcare. Cross Country Healthcare's average media sentiment score of 0.63 beat Genpact's score of 0.59 indicating that Cross Country Healthcare is being referred to more favorably in the media. Company Overall Sentiment Cross Country Healthcare Positive Genpact Positive Is CCRN or G more profitable? Genpact has a net margin of 10.88% compared to Cross Country Healthcare's net margin of -1.41%. Genpact's return on equity of 22.35% beat Cross Country Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Cross Country Healthcare-1.41% 2.56% 1.84% Genpact 10.88%22.35%10.50% Which has preferable valuation and earnings, CCRN or G? Genpact has higher revenue and earnings than Cross Country Healthcare. Cross Country Healthcare is trading at a lower price-to-earnings ratio than Genpact, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCross Country Healthcare$1.34B0.29-$14.56M-$0.53-22.66Genpact$4.77B1.65$513.67M$2.9315.31 Do analysts recommend CCRN or G? Cross Country Healthcare currently has a consensus target price of $17.93, indicating a potential upside of 49.29%. Genpact has a consensus target price of $50.14, indicating a potential upside of 11.76%. Given Cross Country Healthcare's higher possible upside, equities research analysts plainly believe Cross Country Healthcare is more favorable than Genpact.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cross Country Healthcare 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Genpact 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43 SummaryGenpact beats Cross Country Healthcare on 12 of the 15 factors compared between the two stocks. Get Genpact News Delivered to You Automatically Sign up to receive the latest news and ratings for G and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding G and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart G vs. The Competition Export to ExcelMetricGenpactIT Services IndustryComputer SectorNYSE ExchangeMarket Cap$7.71B$16.55B$28.35B$20.63BDividend Yield1.54%1.54%3.12%3.68%P/E Ratio15.3136.9333.0027.27Price / Sales1.6512.791,714.3655.10Price / Cash12.2524.6037.5821.88Price / Book3.314.997.634.60Net Income$513.67M$434.10M$779.73M$995.22M7 Day Performance-0.96%-2.05%0.22%-1.55%1 Month Performance3.96%2.74%6.40%4.38%1 Year Performance31.92%17.06%52,837.52%8.12% Genpact Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GGenpact3.9918 of 5 stars$44.87+1.8%$50.14+11.8%+33.0%$7.71B$4.77B15.31140,000Dividend AnnouncementCCRNCross Country Healthcare3.8414 of 5 stars$12.75-2.0%$17.93+40.6%-20.9%$417.95M$1.34B-24.068,205BRBroadridge Financial Solutions3.9716 of 5 stars$240.32-0.7%$250.83+4.4%+12.0%$28.23B$6.51B36.1414,600Positive NewsGPNGlobal Payments4.994 of 5 stars$80.03-2.2%$110.91+38.6%-19.8%$19.52B$10.11B12.9127,000Trending NewsAnalyst UpgradeAnalyst RevisionGap UpJKHYJack Henry & Associates3.8912 of 5 stars$180.52-0.4%$185.11+2.5%+4.6%$13.15B$2.22B30.757,170Positive NewsAnalyst UpgradeEXLSExlService4.7111 of 5 stars$45.19-0.2%$51.50+14.0%+22.9%$7.35B$1.84B34.2359,500Positive NewsHigh Trading VolumeWEXWEX4.5054 of 5 stars$149.51-1.1%$176.90+18.3%-20.4%$5.12B$2.63B19.276,500Upcoming EarningsEEFTEuronet Worldwide4.6238 of 5 stars$106.00-0.5%$126.86+19.7%-7.9%$4.58B$4.05B15.7010,600MMSMaximus3.6145 of 5 stars$71.29-1.1%$90.00+26.2%-22.6%$4.02B$5.31B14.1741,100Positive NewsPAYPaymentus3.5528 of 5 stars$30.86-0.6%$36.80+19.2%+43.4%$3.86B$871.74M79.131,307High Trading VolumeWUWestern Union4.8952 of 5 stars$8.53-1.0%$10.78+26.4%-35.4%$2.82B$4.21B3.189,100 Related Companies and Tools Related Companies Cross Country Healthcare Competitors Broadridge Financial Solutions Competitors Global Payments Competitors Jack Henry & Associates Competitors ExlService Competitors WEX Competitors Euronet Worldwide Competitors Maximus Competitors Paymentus Competitors Western Union Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:G) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genpact Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Genpact With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free G Stock Alerts